EUVIMEDEUVIMED entdecken
Crossref

Organoids of patient‐derived medullary thyroid carcinoma: The first milestone towards a new in vitro model in dogs

Stephanie Scheemaeker iD, Marine Inglebert, Sylvie Daminet, Martina Dettwiler, Anna Letko, Cord Drögemüller, Martin Kessler, Richard Ducatelle, Sven Rottenberg, Miguel Campos

Veterinary and Comparative Oncology · 2023

DOI: 10.1111/vco.12872 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, 2023. Verfasst von Stephanie Scheemaeker und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Small Animals, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium. Hauptthemen laut MEDLINE: Dog Diseases, Thyroid Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Bijzonder Onderzoeksfonds (BOF) UGent, European Society of Veterinary Endocrinology (ESVE), Fonds Wetenschappelijk Onderzoek (FWO).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Organoid cultures could constitute a valuable in vitro model to explore new treatments for canine (c) medullary thyroid carcinoma (MTC). The study's objectives were to establish and characterize 3D organoid cultures of cMTC using histology and immunohistochemistry (IHC) and to evaluate the effect of antitumor drugs on organoids' viability. Five cMTC tissue samples were used to develop organoid cultures of which one organoid line, named cMTC N°2, could be passaged for an extended period. This cMTC N°2 organoid line was further compared to the primary tumour regarding morphology and IHC expression of thyroid transcription factor‐1 (TTF‐1), thyroglobulin, calcitonin, synaptophysin, vimentin, Ki‐67, cyclooxygenase‐2 (COX‐2), P‐glycoprotein and vascular endothelial growth factor (VEGF). Quality control of the cMTC N°2 organoid line was achieved by a single nucleotide polymorphism (SNP) array of the organoids, primary tumour and healthy blood cells of the same dog. The effect of carboplatin, meloxicam and toceranib phosphate (TOC) on cMTC N°2 organoids' viability was evaluated. The cMTC N°2 organoid line was cultured for 94 days and showed similar histological features with the primary tumour. Immunolabelling for TTF‐1, thyroglobulin, calcitonin and VEGF was similar between the primary tumour and cMTC N°2 organoids. Compared to the primary tumour, organoids showed higher immunolabelling for vimentin and Ki‐67, and lower immunolabelling for synaptophysin, COX‐2 and P‐glycoprotein. The SNP genotype was similar for each chromosome between healthy blood cells, primary tumour and cMTC N°2 organoids. Carboplatin, meloxicam and TOC had no effect on cMTC N°2 organoid cell viability within achievable in vivo concentration range. In conclusion, the cMTC N°2 organoid line is a promising first milestone towards an established in vitro organoid model to explore pathophysiology and new treatment modalities in cMTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dog DiseasesThyroid NeoplasmsSynaptophysinVimentinDogsThyroglobulinCalcitoninATP Binding Cassette Transporter, Subfamily BCyclooxygenase 2MeloxicamKi-67 AntigenCarboplatinAnimalsVascular Endothelial Growth Factor ACarcinoma, NeuroendocrineOrganoids

Stichwörter der Autor:innen

cell culture techniquesdogshistologyimmunohistochemistryneoplasmsthyroid carcinoma

Substanzen

CalcitoninThyroglobulinSynaptophysinVascular Endothelial Growth Factor AVimentinCarboplatinCyclooxygenase 2Ki-67 AntigenMeloxicamATP Binding Cassette Transporter, Subfamily B

Autor:innen und Institutionen

  • Department of Small Animals, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
  • Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Institute of Genetics, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Tierklinik Hofheim, Hofheim am Taunus, Germany.
  • Department of Pathobiology, Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
  • Department of Clinical Veterinary Science, Vetsuisse Faculty, University of Bern, Bern, Switzerland.

ORCID-Profile: Stephanie Scheemaeker

Förderung

  • Bijzonder Onderzoeksfonds (BOF) UGent
  • European Society of Veterinary Endocrinology (ESVE)
  • Fonds Wetenschappelijk Onderzoek (FWO)

Zitieren

APA

Scheemaeker, S., Inglebert, M., Daminet, S., Dettwiler, M., Letko, A., Drögemüller, C., Kessler, M., Ducatelle, R., Rottenberg, S., & Campos, M. (2023). Organoids of patient‐derived medullary thyroid carcinoma: The first milestone towards a new in vitro model in dogs. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.12872

Vancouver

Scheemaeker S, Inglebert M, Daminet S, Dettwiler M, Letko A, Drögemüller C, et al. Organoids of patient‐derived medullary thyroid carcinoma: The first milestone towards a new in vitro model in dogs. Veterinary and Comparative Oncology. 2023. doi:10.1111/vco.12872

BibTeX
@article{Scheemaeker2023,
  author = {Scheemaeker, Stephanie and Inglebert, Marine and Daminet, Sylvie and Dettwiler, Martina and Letko, Anna and Drögemüller, Cord and Kessler, Martin and Ducatelle, Richard and Rottenberg, Sven and Campos, Miguel},
  title = {Organoids of patient‐derived medullary thyroid carcinoma: The first milestone towards a new in vitro model in dogs},
  journal = {Veterinary and Comparative Oncology},
  year = {2023},
  doi = {10.1111/vco.12872}
}
Kostenlos starten →